L&K Biomed Co., Ltd. (156100) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for L&K Biomed Co., Ltd. (156100:KRX), powered by AI.

Current Price
₩5,230
P/E Ratio
-7.2
Market Cap
116.9B
Sector
Healthcare
What is the L&K Biomed Co., Ltd. stock price forecast?

L&K Biomed Co., Ltd. is currently trading at ₩5,230. View real-time AI analysis on Alpha Lenz.

What is L&K Biomed Co., Ltd. insider trading activity?

View the latest insider trading data for L&K Biomed Co., Ltd. on Alpha Lenz.

What is L&K Biomed Co., Ltd.'s P/E ratio?

L&K Biomed Co., Ltd.'s P/E ratio is -7.2.

L&K Biomed Co., Ltd.

KRX · 156100
₩5,230-20(-0.38%)Market closedKRX regular session 09:00–15:30 KST
Ask about L&K Biomed Co., Ltd.'s future dividend policy...
Alpha Chat Insight

L&K Biomed Co., Ltd. trades at a P/E of -7.2 (undervalued) with modest ROE of -37.0%. 3Y revenue CAGR of 25.3% highlights clear growth momentum.

Ask for details

Company Overview

L&K Biomed Co., Ltd. is a prominent player in the medical technology sector, specializing in the development and production of innovative orthopedic solutions. At the core of its operations, the company focuses on the design and manufacture of spinal implant devices. These products are crucial in addressing spinal disorders and enhancing patient mobility, making significant impacts in the healthcare industry. L&K Biomed’s offerings are characterized by cutting-edge technology, ensuring the advancement of medical procedures and patient outcomes. The company operates within a highly specialized niche, catering to a global clientele that includes hospitals, medical centers, and surgical specialists. Its dedication to research and development supports continuous innovation, ensuring that L&K Biomed remains at the forefront of medical technology solutions. By leveraging advanced materials and pioneering surgical techniques, the company plays a vital role in the ever-evolving landscape of orthopedic treatments. L&K Biomed Co., Ltd. is strategically positioned to influence the market with its commitment to quality and innovation, underscoring its significance within the healthcare technology industry.

CEO강국진(단독대표)
SectorHealthcare
IndustryMedical Devices
Employees91

Company Statistics

FY 2025

Profile

₩116,896,530,190Market Cap
₩38,920,486,820Revenue
22.35MShares Out
91Employees

Margins

82.62%Gross
9.03%EBITDA
1.84%Operating
-44.05%Pre-Tax
-43.14%Net

Valuation

-7.17P/E
2.57P/B
3.00EV/Sales
35.88EV/EBITDA
-6.87P/FCF

Growth (CAGR)

25.34%Rev 3Yr
14.99%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-20.17%ROA
-37.05%ROE
-16.90%ROIC

Financial Health

₩3,178,329,830Cash & Cash Equivalents
₩41,669,876,650Net Debt
116.08%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

L&K Biomed Co., Ltd. (ticker: 156100) is a company listed on KRX in the Healthcare sector (Medical Devices). It has approximately 91 employees. Market cap is $116.9B.

The current price is ₩5,230 with a P/E ratio of -7.17x and P/B of 2.57x.

ROE is -37.05% and operating margin is 1.84%. Annual revenue is $38.9B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
L&K Biomed Co., Ltd. (156100) Stock Forecast 2026 ₩5,230 — Price, Financials & Analyst Targets | Alpha Lenz